RaQualia Pharma Inc. (4579.T)
JPY 337.0
(0.9%)
JPY 337.0
(0.9%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 39.05 Million JPY | -77.92% |
| 2022 | 176.83 Million JPY | 909.31% |
| 2021 | 17.52 Million JPY | -35.68% |
| 2020 | 27.23 Million JPY | 1533.95% |
| 2019 | 1.66 Million JPY | -30.8% |
| 2018 | 2.4 Million JPY | 0.0% |
| 2017 | - JPY | 0.0% |
| 2016 | - JPY | 0.0% |
| 2015 | - JPY | 0.0% |
| 2014 | - JPY | 0.0% |
| 2013 | - JPY | 0.0% |
| 2012 | - JPY | 0.0% |
| 2011 | - JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 3.03 Billion JPY | 7674.38% |
| 2024 Q2 | 2.9 Billion JPY | -4.22% |
| 2023 Q2 | 196.1 Million JPY | -5.6% |
| 2023 FY | 39.05 Million JPY | -77.92% |
| 2023 Q4 | 39.05 Million JPY | -86.02% |
| 2023 Q3 | 279.3 Million JPY | 42.42% |
| 2023 Q1 | 207.75 Million JPY | 17.49% |
| 2022 Q1 | 199.59 Million JPY | 1039.24% |
| 2022 Q2 | 199.22 Million JPY | -0.19% |
| 2022 Q4 | 176.83 Million JPY | -5.75% |
| 2022 FY | 176.83 Million JPY | 909.31% |
| 2022 Q3 | 187.62 Million JPY | -5.82% |
| 2021 FY | 17.52 Million JPY | -35.68% |
| 2021 Q1 | 24.86 Million JPY | -8.72% |
| 2021 Q2 | 22.17 Million JPY | -10.83% |
| 2021 Q3 | 19.45 Million JPY | -12.26% |
| 2021 Q4 | 17.52 Million JPY | -9.94% |
| 2020 Q4 | 27.23 Million JPY | 2351.67% |
| 2020 Q2 | 1.29 Million JPY | -12.48% |
| 2020 FY | 27.23 Million JPY | 1533.95% |
| 2020 Q1 | 1.48 Million JPY | -11.1% |
| 2020 Q3 | 1.11 Million JPY | -14.34% |
| 2019 Q1 | 2.22 Million JPY | -7.72% |
| 2019 Q2 | 2.03 Million JPY | -8.32% |
| 2019 Q3 | 1.85 Million JPY | -9.08% |
| 2019 Q4 | 1.66 Million JPY | -10.04% |
| 2019 FY | 1.66 Million JPY | -30.8% |
| 2018 Q3 | 2.59 Million JPY | -6.66% |
| 2018 Q2 | 2.77 Million JPY | -6.27% |
| 2018 Q4 | 2.4 Million JPY | -7.13% |
| 2018 FY | 2.4 Million JPY | 0.0% |
| 2018 Q1 | 2.96 Million JPY | 0.0% |
| 2017 Q2 | - JPY | 0.0% |
| 2017 FY | - JPY | 0.0% |
| 2017 Q4 | - JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2017 Q1 | - JPY | 0.0% |
| 2016 FY | - JPY | 0.0% |
| 2016 Q1 | - JPY | 0.0% |
| 2016 Q2 | - JPY | 0.0% |
| 2016 Q3 | - JPY | 0.0% |
| 2016 Q4 | - JPY | 0.0% |
| 2015 FY | - JPY | 0.0% |
| 2015 Q1 | - JPY | 0.0% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 Q4 | - JPY | 0.0% |
| 2015 Q3 | - JPY | 0.0% |
| 2014 FY | - JPY | 0.0% |
| 2014 Q3 | - JPY | 0.0% |
| 2014 Q4 | - JPY | 0.0% |
| 2014 Q2 | - JPY | 0.0% |
| 2014 Q1 | - JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 Q1 | - JPY | 0.0% |
| 2013 FY | - JPY | 0.0% |
| 2013 Q2 | - JPY | 0.0% |
| 2013 Q4 | - JPY | 0.0% |
| 2012 Q4 | - JPY | 0.0% |
| 2012 Q1 | - JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2012 FY | - JPY | 0.0% |
| 2011 Q4 | - JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2011 FY | - JPY | 0.0% |
| 2010 FY | - JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | 94.909% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 98.048% |
| Linical Co., Ltd. | 1.49 Billion JPY | 97.397% |
| Trans Genic Inc. | 1.32 Billion JPY | 97.057% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -4900.0% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 98.336% |
| AnGes, Inc. | 214.94 Million JPY | 81.833% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 63.453% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 99.938% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | 53.82% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 96.479% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -37.49% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | 95.54% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 97.875% |
| PeptiDream Inc. | 19.63 Billion JPY | 99.801% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | 75.76% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | 90.164% |
| Healios K.K. | 450 Million JPY | 91.322% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | 49.477% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | 94.95% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | 95.044% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | 92.053% |
| StemCell Institute Inc. | 6.67 Million JPY | -484.931% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | 72.835% |